Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Kluge, Michael ^a   Hegerl, Ulrich ^a   Sander, Christian ^a   Dietzel, Jens ^a   Mergl, Roland ^a   Bitter, Istvan ^b   Demyttenaere, Koen ^c   Gusmão, Ricardo ^d   Gonzalez Pinto, Ana ^e,f   Perez Sola, Victor ^f,g   Vieta, Eduard ^f,h   Juckel, Georg ⁱ   Zimmermann, Ulrich S ^j   Bauer, Michael ^j   Sienaert, Pascal ^c   Quintão, Sónia ^d   Edel, Marc Andreas ⁱ   Bolyos, Csilla ^b   Ayuso Mateos, Jose Luis ^f,k,l   López García, Pilar ^f,l  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LISBON   (Portugal)

^e HOSPITAL TXAGORRITXU   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ RUHR UNIVERSITY BOCHUM   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^l Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

more..

Author keywords

Bipolar disorder; EEG; Mania; Methylphenidate; Psychostimulants; Vigilance

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ACTIMETRY; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84874708766     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-71     Document Type: Article

References (51)

1. Keck PE, McElroy SL, Bennett JA. Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatr 1996, 57(Suppl 13):13-18.
2. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000, 2:261-268.
3. Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatr 2009, 43:1096-1104.
4. Hegerl U, Sander C, Olbrich S, Schoenknecht P. Are psychostimulants a treatment option in mania?. Pharmacopsychiatry 2009, 42:169-174.
5. Hegerl U, Hensch T. The vigilance regulation model of affective disorders and ADHD. Neurosci Biobehav Rev 2012, in press.
6. Hegerl U, Himmerich H, Engmann B, Hensch T. Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment?. Curr Opin Psychiatry 2010, 23:1-7.
7. Bente D. [Vigilance: psychophysiologic aspects]. Verh Dtsch Ges Inn Med 1977, 83:945-952.
8. Ulrich G. Electroencephalographic response prediction of antipsychotic drug treatment in acutely ill patients and of long-term prophylactic treatment with lithium salts. Pharmacopsychiatry 1994, 27(Suppl 1):24-26.
9. Eysenck HJ. Biological dimensions of personality. Handbook of Personality: Theory and research 1990, 244-276. Guilford Press, New York, Pervin LA.
10. Zuckerman M. The psychophysiology of sensation seeking. J Pers 1990, 58:313-345.
11. Van Sweden B. Disturbed vigilance in mania. Biol Psychiatry 1986, 21:311-313.
12. Small JG, Milstein V, Malloy FW, Medlock CE, Klapper MH. Clinical and quantitative EEG studies of mania. J Affect Disord 1999, 53:217-224.
13. Wehr TA. Improvement of depression and triggering of mania by sleep deprivation. JAMA 1992, 267:548-551.
14. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008, 165:820-829.
15. Barbini B, Bertelli S, Colombo C, Smeraldi E. Sleep loss, a possible factor in augmenting manic episode. Psychiatr Res 1996, 65:121-125.
16. Riemann D, Voderholzer U, Berger M. Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 2002, 45(Suppl 1):7-12.
17. Benazzi F. Severe mania following abrupt nicotine withdrawal. Am J Psychiatry 1989, 146:1641.
18. Labbate LA. Nicotine cessation, mania, and depression. Am J Psychiatry 1992, 149:708.
19. Diaz FJ, James D, Botts S, Maw L, Susce MT, de LJ. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord 2009, 11:154-165.
20. Baethge C, Tondo L, Lepri B, Baldessarini RJ. Coffee and cigarette use: association with suicidal acts in 352 Sardinian bipolar disorder patients. Bipolar Disord 2009, 11:494-503.
21. Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005, 57:1467-1473.
22. Singh MK, DelBello MP, Kowatch RA, Strakowski SM. Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disord 2006, 8:710-720.
23. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:456-463.
24. Moen MD, Keam SJ. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 2009, 23:1057-1083.
25. Sangal RB, Sangal JM. Rating scales for inattention and sleepiness are correlated in adults with symptoms of sleep disordered breathing syndrome, but not in adults with symptoms of attention-deficit/hyperactivity disorder. Sleep Med 2004, 5:133-135.
26. Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2010, 25:107-115.
27. Sobanski E, Schredl M, Kettler N, Alm B. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 2008, 31:375-381.
28. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol 2003, 13:123-136.
29. Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O'Connor B, Majumdar A, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol 2008, 18:573-588.
30. Brown WA, Mueller B. Alleviation of Manic Symptoms with Catecholamine Agonists. Am J Psychiatry 1979, 136:230-231.
31. Garvey MJ, Hwang S, Teubnerrhodes D, Zander J, Rhem C. Dextroamphetamine Treatment of Mania. J Clin Psychiatr 1987, 48:412-413.
32. Clower CG. Treatment of Mania with Dextroamphetamine. J Clin Psychiatr 1988, 49:283.
33. Max JE, Richards L, Hamdanallen G. Case-Study - Antimanic Effectiveness of Dextroamphetamine in A Brain-Injured Adolescent. J Am Acad Child Adolesc Psychiatr 1995, 34:472-476.
34. Bschor T, Muller-Oerlinghausen B, Ulrich G. Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: a case study. Clin Electroencephalogr 2001, 32:36-39.
35. Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry 2010, 67:e55-e57.
36. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008, 69:87-94.
37. Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006, 26:653-656.
38. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006, 163:1149-1152.
39. Gelperin K, Phelan K. Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. FD Report PID D050243 2006, US Food and Drug Administration, http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_07_01_safetyreview.pdf. 3-3.
40. Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004, 18:243-250.
41. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
42. Montoya A, Valladares A, Lizan L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 2011, 9:18.
43. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatr Res 1997, 73:159-171.
44. Olbrich S, Mulert C, Karch S, Trenner M, Leicht G, Pogarell O, et al. EEG-vigilance and BOLD effect during simultaneous EEG/fMRI measurement. NeuroImage 2009, 45:319-332.
45. Purdon SE. The Screen for Cognitive Impairment in Psychiatry (SCIP): Administration Manual and Normative Data 2005, PNL Inc, Edmonton, Alberta.
46. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993, 150:885-890.
47. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994, 50:1029-1041.
48. Dixon JRJ. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur 1998, 6:65-74.
49. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009, 23:194-205.
50. Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012, 138:247-258.
51. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122:27-38.